VIR
Vir Biotechnology, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -18.2% ·
share flow +1.0% ·
net new positions -20.0%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 87 | -1 | 78.79M | $802.94M | +8 | −9 |
| Q1 2026 | 91 | +1 | 69.76M | $624.09M | +9 | −8 |
| Q4 2025 | 90 | +1 | 66.65M | $401.74M | +1 | — |
| Q3 2025 | 15 | 0 | 49.25M | $281.20M | — | — |
| Q2 2025 | 12 | 0 | 46.48M | $234.27M | — | — |
| Q1 2025 | 9 | -2 | 12.32M | $79.81M | — | −2 |
| Q4 2024 | 11 | 0 | 12.20M | $89.54M | +1 | −1 |
| Q3 2024 | 10 | -2 | 8.42M | $63.10M | — | −2 |
| Q2 2024 | 12 | — | 10.84M | $96.49M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 5.73M | +12.9% | $37.11M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 2.30M | +4.5% | $14.88M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 2.30M | +4.5% | $14.88M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 1.62M | +496.2% | $10.48M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 1.62M | +496.2% | $10.48M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 1.12M | -9.5% | $7.26M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 506.70K | +0.9% | $3.28M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 506.70K | +0.9% | $3.28M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Millennium Management ✦ | 433.38K | -74.7% | $2.81M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 272.54K | +10.8% | $1.77M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 268.30K | +2088.4% | $1.74M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 268.30K | +2088.4% | $1.74M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 268.30K | +2088.4% | $1.74M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 268.30K | +2088.4% | $1.74M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 268.30K | +2088.4% | $1.74M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 74.68K | +4.7% | $484,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Point72 Asset Management | $6.23M | was 0.0% |
| Marshall Wace | $172,908 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 251 holders, 138.04M shares, $1.23B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.